Neurocrine Biosciences, Inc. (NBIX)
155.50
+0.83
(+0.54%)
USD |
NASDAQ |
May 21, 16:00
155.58
+0.08
(+0.05%)
After-Hours: 19:59
Neurocrine Biosciences Research and Development Expense (TTM) : 1.049B for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Soleno Therapeutics, Inc. | 38.38M |
| Biogen, Inc. | 1.607B |
| Nuvalent, Inc. | 316.16M |
| Marker Therapeutics, Inc. | 11.51M |
| Denali Therapeutics, Inc. | 406.40M |